Next Article in Journal
The Combined Use of Stem Cells and Platelet Lysate Plasma for the Treatment of Erectile Dysfunction: A Pilot Study–6 Months Results
Previous Article in Journal
Primer for Mainstreaming Mind-Body Techniques for Extreme Climates-Insights and Future Directions
 
 
Article

High Serum Phosphate Level as a Risk Factor to Determine Renal Prognosis in Autosomal Dominant Polycystic Kidney Disease: A Retrospective Study

1
Department of Nephrology, Tokyo Women’s Medical University, Tokyo 162-8666, Japan
2
Clinical Research Division for Polycystic Kidney Disease, Department of Nephrology, Tokyo Women’s Medical University, Tokyo 162-8666, Japan
3
Department of Blood Purification, Kidney Center, Tokyo Women’s Medical University, Tokyo 162-8666, Japan
*
Author to whom correspondence should be addressed.
Medicines 2020, 7(3), 13; https://doi.org/10.3390/medicines7030013
Received: 13 February 2020 / Revised: 9 March 2020 / Accepted: 10 March 2020 / Published: 12 March 2020
(This article belongs to the Section Nephrology and Urology)
Background: Serum phosphate levels, which are associated with the progression of renal dysfunction in chronic kidney disease, in patients with autosomal dominant polycystic kidney disease (ADPKD) are lower than those in patients with other kidney diseases. However, their role in ADPKD remains unclear. This study aimed to determine whether serum phosphate levels could have an association with renal prognoses among patients with ADPKD. Methods: In total, 55 patients with PKD1 or PKD2 mutations but not undergoing dialysis were evaluated. Data regarding serum phosphate levels were collected, and Cox regression analyses were used to calculate hazard ratios (HRs) with renal replacement therapy as the endpoint. Results: The median (quartile 1; quartile 3) serum phosphate concentration was 3.4 (3.1; 3.9) mg/dL, and the estimated glomerular filtration rate (eGFR) was 39.5 (17.6; 65.7) mL/min/1.73 m2. The multivariate analysis that included age, PKD1 mutation, eGFR, urinary protein excretion, hyperuricemia, and serum phosphate determined that eGFR (HR, 0.82; 95% confidence interval (CI), 0.74–0.90; p < 0.0001) and serum phosphate (HR, 6.78; 95% CI, 1.94–34.02; p = 0.0021) were independently associated with renal replacement therapy. Conclusions: We found that serum phosphate levels were significantly associated with poor renal prognoses in patients with ADPKD. View Full-Text
Keywords: phosphate; polycystic kidney disease; fibroblast growth factor 23; klotho; renal prognosis phosphate; polycystic kidney disease; fibroblast growth factor 23; klotho; renal prognosis
Show Figures

Figure 1

MDPI and ACS Style

Sato, M.; Kataoka, H.; Ushio, Y.; Manabe, S.; Watanabe, S.; Akihisa, T.; Makabe, S.; Yoshida, R.; Iwasa, N.; Mitobe, M.; Hanafusa, N.; Tsuchiya, K.; Nitta, K.; Mochizuki, T. High Serum Phosphate Level as a Risk Factor to Determine Renal Prognosis in Autosomal Dominant Polycystic Kidney Disease: A Retrospective Study. Medicines 2020, 7, 13. https://doi.org/10.3390/medicines7030013

AMA Style

Sato M, Kataoka H, Ushio Y, Manabe S, Watanabe S, Akihisa T, Makabe S, Yoshida R, Iwasa N, Mitobe M, Hanafusa N, Tsuchiya K, Nitta K, Mochizuki T. High Serum Phosphate Level as a Risk Factor to Determine Renal Prognosis in Autosomal Dominant Polycystic Kidney Disease: A Retrospective Study. Medicines. 2020; 7(3):13. https://doi.org/10.3390/medicines7030013

Chicago/Turabian Style

Sato, Masayo, Hiroshi Kataoka, Yusuke Ushio, Shun Manabe, Saki Watanabe, Taro Akihisa, Shiho Makabe, Rie Yoshida, Naomi Iwasa, Michihiro Mitobe, Norio Hanafusa, Ken Tsuchiya, Kosaku Nitta, and Toshio Mochizuki. 2020. "High Serum Phosphate Level as a Risk Factor to Determine Renal Prognosis in Autosomal Dominant Polycystic Kidney Disease: A Retrospective Study" Medicines 7, no. 3: 13. https://doi.org/10.3390/medicines7030013

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop